Medical Journal of The Islamic Republic of Iran (MJIRI)
Iran University of Medical Sciences
Thu, Nov 21, 2024
[Archive]
Volume 36, Issue 1 (1-2022)
Med J Islam Repub Iran 2022 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Rashidian H, Haghdoost A A, Daroudi R, Raadabadi M, Ebadzadeh M R, Zendehdel K. Estimating the Prevalence of Bladder Cancer by Stage in Iran as a Developing Country. Med J Islam Repub Iran 2022; 36 (1) :283-287
URL: http://mjiri.iums.ac.ir/article-1-7754-en.html
URL: http://mjiri.iums.ac.ir/article-1-7754-en.html
Hamideh Rashidian 
, Ali Akbar Haghdoost , Rajabali Daroudi , Mehdi Raadabadi , Mohammad Reza Ebadzadeh , Kazem Zendehdel
, Ali Akbar Haghdoost , Rajabali Daroudi , Mehdi Raadabadi , Mohammad Reza Ebadzadeh , Kazem Zendehdel
Cancer Research Center, & Cancer Biology Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran , kzendeh@tums.ac.ir
Abstract: (1155 Views)
Background: Bladder cancer is among the 10 most common cancers globally and in Iran. The prevalence rate is a crucial metric for both estimating disease burden and policymakers. On the other hand, bladder cancer is a heterogeneous disease with different stages, high recurrence, and progression rate. In planning treatment procedures, it is important to know the prevalence of bladder cancer by stages. In the current study, we aimed to estimate the 5-year prevalence of bladder cancer by stages using the Markov model.
Methods: This was a simulation study. To estimate the 5-year prevalence of bladder cancer by stages, we used the Markov model with a time horizon of 5 years following diagnosis. We simulated the natural history of bladder cancer using a literature review. We extracted survival rate, stage-specific recurrence, and progression rate using local and international publications and expert opinion. In addition, we used the Iranian life table and extracted probabilities of mortality due to other causes of death.
Results: Five-year prevalence of bladder cancer for the year 2018 was estimated at 21,807 patients. Non- muscle-invasive bladder cancer accounted for around 68% of all cases, with 42% in the Ta low-grade stage. About 32% of bladder cancer prevalent cases were muscle-invasive bladder cancer patients, from which about 8% had metastatic tumors.
Conclusion: Researchers and policymakers can utilize the findings of this study to conduct economic burden analyses and plan resource allocation.
Methods: This was a simulation study. To estimate the 5-year prevalence of bladder cancer by stages, we used the Markov model with a time horizon of 5 years following diagnosis. We simulated the natural history of bladder cancer using a literature review. We extracted survival rate, stage-specific recurrence, and progression rate using local and international publications and expert opinion. In addition, we used the Iranian life table and extracted probabilities of mortality due to other causes of death.
Results: Five-year prevalence of bladder cancer for the year 2018 was estimated at 21,807 patients. Non- muscle-invasive bladder cancer accounted for around 68% of all cases, with 42% in the Ta low-grade stage. About 32% of bladder cancer prevalent cases were muscle-invasive bladder cancer patients, from which about 8% had metastatic tumors.
Conclusion: Researchers and policymakers can utilize the findings of this study to conduct economic burden analyses and plan resource allocation.
Type of Study: Original Research |
Subject:
Biostatistics and Epidemiology
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
